Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
Completed · Phase 1
Conditions studied: Non-Small Cell Lung Cancer
In brief
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
Key facts
- Study ID
- NCT00633529
- Run by
- EMD Serono
- People needed
- 36
- Starts
- 2007-11-01
- Expected to finish
- 2011-03-01
- Last updated by the study team
- 2013-10-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Centers of Florida — Ocoee, Florida, United States
- Central Indiana Cancer Centers — Indianapolis, Indiana, United States
- New York Oncology Hematology P.C. — Albany, New York, United States
- Mary Crowley Medical Research Center — Dallas, Texas, United States
- Cancer Therapy and Research Center — San Antonio, Texas, United States
- Tyler Cancer Center — Tyler, Texas, United States
- Virginia Oncology Associates — Norfolk, Virginia, United States
- Northwest Cancer Specialists — Vancouver, Washington, United States
- Yakima Valley Memorial Hospital/North Shore Cancer Lodge — Yakima, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.